Company NovMetaPharma Co., Ltd.

Equities

A229500

KR7229500004

Biotechnology & Medical Research

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sector Bio Therapeutic Drugs

End-of-day quote Korea S.E. Other stock markets 23:00:00 06/06/2024 BST			5-day change	1st Jan Change
5,430 ^KRW	+1.50%		-13.95%	-73.51%

05-27	NovMetaPharma Co., Ltd. cancelled the acquisition of SK Securities No.8 Special Purpose Acquisition Company in a reverse merger transaction.	CI
2023	NovMetaPharma Co., Ltd. agreed to acquire SK Securities No.8 Special Purpose Acquisition Company in a reverse merger transaction	CI

NovMetaPharma Co., Ltd. is a Korea-based company mainly engaged in the development and sale of pharmaceuticals. The Company operates its business through two segments. The New Drug Development segment is involved in the development and sale of diabetes treatment, obesity treatment, osteoporosis treatment, alzheimer's disease treatment, and autoimmune enhancers. The Health Functional Food segment is engaged in the manufacturing and sale of health functional food related to blood sugar, prostate health, comprehensive minerals, and cognitive improvement. It also produces and sells vinegar drinks. The Company distributes its products within the domestic market and to overseas markets, including America and China.

KRW in Million	2022	Weight	2023	Weight	Delta
Health Functional Food 100.0 %	31	100.0 %	14	100.0 %	-56.00%

KRW in Million	2022	Weight	2023	Weight	Delta
South Korea 100.0 %	31	100.0 %	14	100.0 %	-56.00%

Managers	Title	Age	Since
Hoi-Yoon Jung CEO	Chief Executive Officer	45	-
Seon-Wook Hwang CEO	Chief Executive Officer	64	03/11/10
Heon-Jong Lee BRD	Director/Board Member	54	31/03/11
Johan Auwerx BRD	Director/Board Member	-	-
Chun-Su Lee AUD	Comptroller/Controller/Auditor	62	30/03/15

Members of the board	Title	Age	Since
Johan Auwerx BRD	Director/Board Member	-	-
Seon-Wook Hwang CEO	Chief Executive Officer	64	03/11/10
Heon-Jong Lee BRD	Director/Board Member	54	31/03/11
Mun-Jin Song BRD	Director/Board Member	54	31/12/13
Sang-Joon Kim BRD	Director/Board Member	63	14/06/18
In-Gyu Lee BRD	Director/Board Member	67	12/12/17
Jong-Man Seol BRD	Director/Board Member	65	26/03/19
Gyung-Tae Kim BRD	Director/Board Member	67	20/09/16
Hoi-Yoon Jung CEO	Chief Executive Officer	45	-

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	11,090,448	7,443,358 ( 67.12 %)	135 ( 0.001217 %)	67.12 %

Name	Equities	%	Valuation
Seon-Wook Hwang 9.360 %	1,038,030	9.360 %	17 M ₩
Mun-Jin Song 7.188 %	797,137	7.188 %	13 M ₩
Mi-jin Song 7.188 %	797,137	7.188 %	13 M ₩
Mun-Gi Song 3.594 %	398,568	3.594 %	6 M ₩
Jong-soon Song 3.594 %	398,568	3.594 %	6 M ₩
KX INNOVATION CO., LTD. 1.286 %	142,655	1.286 %	2 M ₩
Heon-Jong Lee 0.7766 %	86,128	0.7766 %	1 M ₩
Won-gyu Son 0.4833 %	53,596	0.4833 %	859 885 ₩
Chun-Su Lee 0.4406 %	48,860	0.4406 %	783 902 ₩
Jae-wook Kim 0.1711 %	18,978	0.1711 %	304 480 ₩

NovMetaPharma Co., Ltd.

13/F, Trees building 727 Eonju-ro

06050, Seoul

http://www.novmeta.com

address NovMetaPharma Co., Ltd.(A229500)

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
NOVMETAPHARMA CO., LTD.	-73.51%	35.32M
VERTEX PHARMACEUTICALS INCORPORATED	+18.72%	125B
REGENERON PHARMACEUTICALS, INC.	+14.19%	108B
BIONTECH SE	-4.93%	24.21B
ARGENX SE	+3.23%	22.78B
GENMAB A/S	-10.44%	17.96B
WUXI APPTEC CO., LTD.	-41.74%	16.43B
BEIGENE, LTD.	-13.31%	16.37B
NEUROCRINE BIOSCIENCES, INC.	+2.44%	13.58B
SAREPTA THERAPEUTICS, INC.	+27.89%	11.66B

Bio Therapeutic Drugs